HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fox, E. J. Search for Related Content PubMed PubMed Citation Articles by Fox, E. J.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Mechanism of action of mitoxantrone

From the MS Clinic of Central Texas, Round Rock, Texas.

Address correspondence and reprint requests to: Dr. Edward J. Fox, MS Clinic of Central Texas, 7200 Wyoming Springs Dr., Suite 1100, Round Rock, TX 78681; e-mail: FoxTex{at}aol.com

Mitoxantrone, a synthetic anthracenedione, was developed in the 1980s as a doxorubicin analogue in a program to find a cytotoxic agent with decreased cardiotoxicity compared with doxorubicin. It was approved by the FDA in 1987 for the treatment of adult acute myeloid leukemia and in 1996 for symptomatic hormone-refractory prostate cancer. In 2000, mitoxantrone was approved by the FDA for the treatment of worsening relapsing–remitting multiple sclerosis (MS), secondary progressive MS, and progressive-relapsing MS. Mitoxantrone is taken up rapidly by tissues, from which it is released slowly, and the terminal half-life ranges from 8.9 hours to 9 days. The highest concentrations of the drug are typically found in the thyroid, liver, and heart, and the drug persists in the body for as long as 272 days. Mitoxantrone is effective in reducing disease progression through a variety of different mechanisms of action. For example, it suppresses the proliferation of T cells, B cells, and macrophages. It impairs antigen presentation and decreases the secretion of proinflammatory cytokines. Mitoxantrone enhances T-cell suppressor function and inhibits B-cell function and antibody production. Finally, it inhibits macrophage-mediated myelin degradation. Compared with interferon betas, mitoxantrone has a broad range of actions and has effects on many different types of immune cells.

This article has been cited by other articles:

				T Vollmer, H Panitch, A Bar-Or, J Dunn, M. Freedman, S. Gazda, D Campagnolo, F Deutsch, and D. Arnold Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis Multiple Sclerosis, June 1, 2008; 14(5): 663 - 670. [Abstract] [PDF]

				L. Deng, P. Dai, A. Ciro, D. F. Smee, H. Djaballah, and S. Shuman Identification of Novel Antipoxviral Agents: Mitoxantrone Inhibits Vaccinia Virus Replication by Blocking Virion Assembly J. Virol., December 15, 2007; 81(24): 13392 - 13402. [Abstract] [Full Text] [PDF]

				M. A. Bewick, M. S.C. Conlon, and R. M. Lafrenie Polymorphisms in XRCC1, XRCC3, and CCND1 and Survival After Treatment for Metastatic Breast Cancer J. Clin. Oncol., December 20, 2006; 24(36): 5645 - 5651. [Abstract] [Full Text] [PDF]